Because IGF1 acts to increase Akt/mTOR signaling and mTOR inhibition is effective in reducing certain hallmarks of epilepsy and posttraumatic epilepsy (Buckmaster and Lew, 2011; Guo et al., 2013; Butler et al., 2015; Jiang et al., 2015; Hester et al., 2016), it is important to determine whether IGF1-based therapies for TBI increase the risk for posttraumatic epilepsy. The gene discussed is AKT1; the disease is epilepsy.